Home Products Most Popular Contact
No items in your cart.
The page below is a sample from the LabCE course Cardiac Biomarkers. Access the complete course and earn ASCLS P.A.C.E.-approved continuing education credits by subscribing online.

Learn more about Cardiac Biomarkers (online CE course) »
How to Subscribe
MLS & MLT Comprehensive CE Package
Includes 111 CE courses, most popular
$95 Add to cart
Pick Your Courses
Up to 8 CE hours
$50 Add to cart
Individual course$20 Add to cart

Introduction

In 2015, 41.5 percent of the U.S. population had at least one cardiovascular disease (CVD) condition. These include elevated blood pressure, coronary heart disease, stroke, congestive heart failure or atrial fibrillation. In 2035, the number of Americans with CVD is projected to rise to 131.2 million, or 45 percent of the total U.S. population. Congestive heart failure remains the leading cause of hospitalization in those aged 65 and older. Health care costs for cardiovascular disease (CVD), which includes coronary artery disease (CAD) and coronary heart disease (CHD) account for more than $500 billion each year. And while cancer has been increasing as a top cause of total deaths, heart disease remains at the top of the list, as the number one cause of death in the US in 2018. Appropriate care for cardiovascular disease and infarction means timely care. These patients often present with high acuity and the laboratory's role in detecting and monitoring the underlying disease is essential. As many as 5% of patients with an acute myocardial infarction (AMI) are misdiagnosed in the emergency department and discharged. The laboratory's role is especially important in individuals with AMI who present with AMI symptoms but have a nondiagnostic electrocardiogram (ECG).
Cardiovascular Disease: A costly Burden for America, Projections through 2035. American Heart Association, 2017. https://healthmetrics.heart.org/wp-content/uploads/2017/10/Cardiovascular-Disease-A-Costly-Burden.pdf page 7, Accessed August 22, 2018.